Clear cell renal carcinoma brain metastases treatment

• Severe hypercalcemia as the initial presentation of renal cell carcinoma: a diagnostic case report
• A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
• Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience
• Renal vein aneurysm secondary to renal cell carcinoma
• Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review
• Predictive Factors for Oligometastatic Renal Cell Carcinoma Treated with Stereotactic Radiation: A Retrospective Study
• Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment
• TMED9: a potential therapeutic target and prognostic marker in glioma and its implications across pan-cancer contexts

The brain metastases treatment from clear cell renal carcinoma (ccRCC) typically involves a multidisciplinary approach, which may include the following options:

Surgery: see Brain metastases surgery

Radiation Therapy: see Brain metastases radiotherapy

Whole Brain Radiation Therapy (WBRT): This is often used for multiple brain metastases. It can help reduce tumor size and prevent further growth. Stereotactic Radiosurgery (SRS): This is a more precise form of radiation therapy that targets specific tumors while minimizing damage to surrounding healthy tissue. It is often used for patients with one to three brain metastases. Systemic Therapy:

Targeted Therapy: Agents like tyrosine kinase inhibitors (TKIs) such as sunitinib and pazopanib are commonly used for ccRCC and may be effective in treating metastatic disease. Immunotherapy: Agents like nivolumab (an anti-PD-1 antibody) and ipilimumab (an anti-CTLA-4 antibody) are used in advanced RCC and can be considered for patients with brain metastases. Corticosteroids: These may be prescribed to reduce edema and alleviate symptoms associated with brain metastases.

Clinical Trials: Participation in clinical trials may provide access to new therapies that are being investigated for efficacy in treating brain metastases from ccRCC.

The choice of treatment depends on various factors, including the number and size of brain metastases, the patient’s overall health, and the presence of other metastases or comorbidities. A consultation with a medical oncologist, neurosurgeon, and radiation oncologist is essential to develop an individualized treatment plan.